Segmentectomy for Ground Glass-dominant Invasive Lung Cancer

The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are:The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm;The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.

Inclusion Criteria:Patients who sign the informed consent form and are willing to complete the study according to the plan;Aged from 18 to 80 years old;ECOG equals 0 or 1;Not receiving lung cancer surgery before;Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;Ground glass-dominant lung nodulesConsolidation-to-tumor ratio (CTR) ranges from 0 to 0.5, and tumor size ranges from 2 to 3cm;cN0 without distant metastasis;Tumors could be completely resected assed by surgeons;Not receiving chemotherapy or radiotherapy before.Exclusion Criteria:CTR is not 0-0.5, or size is not 2-3cm;Tumors could not be completely resected assed by surgeons;Not lung adenocarcinoma diagnosed cytologically or pathologically;Receiving lung cancer surgery before;Receiving radiotherapy or chemotherapy.